entertainment -WSS

entertainment

author：Wikipedia 2025-09-28 02:29:02 - browse：851

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： Harvard's Jason Buenrostro wins MacArthur grant for genetics work

focus

WSS

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

H5N1 virus can be tracked in retail milk, scientists say

Investigation reveals sickle cell patients pressured into sterilizations

Listen: A conversation with researcher Kevin Esvelt on biosecurity

Study on Amgen’s bispecific immunotherapy produces positive data

Why a market frenzy over new weight loss drugs defies logic

hotspot

entertainment

Wikipedia

Guidelines to prevent youth baseball injuries need more muscle

Listen: More tumult at BIO & coercive care for sickle cell patients

The cancer drug shortage isn’t new — and neither are the solutions

How AI can help patients find reliable information about doctors

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Results on Novartis prostate cancer therapy could expand its use

What does generative AI mean for health care? We asked experts

Addressing health care workers' trauma can help fight burnout

Bright Health sells Medicare Advantage business to Molina

Listen: A conversation with researcher Kevin Esvelt on biosecurity

hotspot

Listen: More tumult at BIO & coercive care for sickle cell patients

Bird flu surveillance in wastewater gets boost from consortium

Smaller biotechs seek to piggyback on weight loss drug boom

As a primary care physician, here's how I hope to partner with AI

Listen: More tumult at BIO & coercive care for sickle cell patients

At flashy new research hub, AstraZeneca lays out ambitious growth goals

focus

Wikipedia

entertainment

hotspot